Overview

The RegiSCAR Score for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a structured, validated scoring instrument developed by the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) group to standardize the classification of suspected DRESS cases in clinical practice and research settings. The score integrates clinical, hematological, biochemical, and histopathological criteria into a composite numeric total that classifies presentations into four ordered diagnostic categories: no case, possible, probable, and definite DRESS.

Prior to the development of the RegiSCAR scoring system, DRESS diagnosis relied on heterogeneous and inconsistently applied clinical criteria, resulting in marked variability in case ascertainment across institutions and clinical studies. The RegiSCAR score addresses this problem by providing an explicit, reproducible algorithm that can be applied systematically at the bedside or retrospectively in pharmacovigilance and case registry review. Its widespread adoption in dermatology, allergy-immunology, internal medicine, and critical care has substantially improved the comparability of DRESS cohort data internationally and has reinforced a common diagnostic standard for this life-threatening drug hypersensitivity syndrome.

DRESS Syndrome: Pathophysiology and Clinical Background

DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) is a severe, potentially life-threatening systemic drug hypersensitivity reaction characterized by an extensive skin rash, fever, lymphadenopathy, hematological abnormalities (most notably eosinophilia and atypical lymphocytosis), and multi-organ involvement. It is distinct from other severe cutaneous adverse reactions (SCARs) including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP) in both its pathomechanism, the breadth of systemic involvement, the characteristic temporal delay between drug exposure and symptom onset, and its prolonged clinical course.

DRESS carries a mortality rate of approximately 10% in published cohorts, primarily attributable to hepatic failure, myocarditis, pneumonitis, and hemophagocytic lymphohistiocytosis (HLH) as complications. Long-term sequelae including autoimmune disorders (thyroiditis, type 1 diabetes mellitus, autoimmune hemolytic anemia, systemic lupus erythematosus) are reported in a significant proportion of survivors, likely reflecting the profound and prolonged immune dysregulation that characterizes the syndrome.

Epidemiology

The precise incidence of DRESS is difficult to establish given historical inconsistency in diagnostic criteria, but estimated incidence ranges from 1 in 1,000 to 1 in 10,000 drug exposures for high-risk medications. Aromatic anticonvulsants (carbamazepine, phenytoin, phenobarbital, lamotrigine), sulfonamide antibiotics (sulfamethoxazole, dapsone), allopurinol, minocycline, vancomycin, and abacavir represent the most commonly implicated drug classes in published case series. Certain implicated drugs have well-characterized pharmacogenomic associations that dramatically increase DRESS risk in genetically susceptible individuals.

Pathomechanism

The immunopathogenesis of DRESS involves a complex, multistep process that remains incompletely understood but has several well-characterized components. The classical model involves three interacting factors: a reactive drug metabolite capable of acting as a hapten or pro-hapten, an underlying state of viral reactivation (particularly of herpesviruses), and a genetically determined susceptibility of the host immune system to mount an aberrant and sustained response.

The delayed onset of DRESS (typically 2 to 8 weeks after starting the culprit drug, contrasting with immediate hypersensitivity reactions occurring within hours) reflects the time required for the development of a drug-specific T-cell response, clonal expansion of reactive T-cell populations, and subsequent engagement of innate immune effector mechanisms. The characteristic herpesviridae reactivation observed in DRESS (HHV-6 in approximately 60% of cases, HHV-7, EBV, and CMV reactivation also reported) is now considered a core pathological feature rather than a coincidental finding, and the sequential pattern of viral reactivation has been proposed as a biological marker of disease progression and severity.

The regulatory T-cell (Treg) compartment is profoundly dysregulated in DRESS, with transient expansion of FOXP3-expressing Tregs during the acute phase followed by a period of Treg depletion that may underlie the paradoxical worsening sometimes observed after initial clinical improvement and the subsequent development of autoimmune sequelae. Expansion of CD4+ and CD8+ drug-specific T cells, polarization toward Th2 and Th17 cytokine profiles, and massive cytokine release (including IL-5, a primary driver of eosinophilia, and IL-6, IL-10, and TNF-alpha) collectively mediate the systemic inflammation and organ injury that define the syndrome.

Pharmacogenomic Associations

Several HLA alleles have been identified as strong genetic risk factors for DRESS with specific culprit drugs, with some associations demonstrating near-complete positive predictive value in defined ethnic populations:

• HLA-B*58:01 and allopurinol-induced DRESS/SJS-TEN: The strongest and best-characterized pharmacogenomic association in drug hypersensitivity. HLA-B*58:01 confers an odds ratio of over 500 for allopurinol-induced severe cutaneous adverse reactions in Han Chinese, Korean, and Thai populations. Prospective HLA-B*58:01 screening before allopurinol initiation is now a standard of care recommendation in multiple Asian countries and is increasingly adopted in diverse populations.
• HLA-A*31:01 and carbamazepine-induced DRESS: HLA-A*31:01 is associated with carbamazepine-induced DRESS across European and Japanese populations (odds ratio approximately 25 to 33 in Europeans). Unlike HLA-B*15:02 (which is associated with carbamazepine-induced SJS-TEN specifically in Han Chinese), HLA-A*31:01 is relevant across ethnic groups for the DRESS phenotype.
• HLA-B*57:01 and abacavir hypersensitivity: HLA-B*57:01 is associated with abacavir hypersensitivity syndrome, which shares features with DRESS. Prospective HLA-B*57:01 screening before abacavir initiation has become a universal standard embedded in HIV treatment guidelines globally.
• HLA-DRB1*01:01 and dapsone-induced DRESS: Associated with dapsone hypersensitivity syndrome in Chinese and Korean populations, guiding screening recommendations in high-risk populations receiving dapsone for leprosy, Pneumocystis prophylaxis, or dermatological indications.

Characteristic Clinical Features

DRESS presents with a constellation of clinical features that, when complete, are highly distinctive but which may be variably present or sequentially emergent during the clinical course, making early diagnosis challenging.

Skin Manifestations

The cutaneous eruption in DRESS is typically a morbilliform (maculopapular) exanthem that begins on the face and upper trunk before spreading to involve a large proportion of the body surface area, frequently exceeding 50% BSA involvement at peak. The rash characteristically shows facial edema, particularly periorbital puffiness, which is one of the most visually distinctive features of DRESS and is absent in most other drug eruptions. The rash may develop varying degrees of infiltration (giving it a palpable quality distinct from the flat erythema of simple drug exanthem), scaling, and in some cases purpuric components particularly on the lower extremities. Mucosal involvement, when present, is typically limited and superficial, contrasting with the severe mucosal erosion of SJS-TEN.

The rash may paradoxically worsen in the weeks following drug discontinuation, reflecting the self-sustaining immunological process that characterizes DRESS and can persist or relapse for months after the culprit drug is stopped. This prolonged and relapsing course is diagnostically important and is reflected in the RegiSCAR criterion requiring resolution of more than 15 days.

Fever

High-grade fever (typically above 38.5°C) is present at onset or in the early course of DRESS in the majority of patients and often precedes the skin rash by several days, during which the presentation may be mistaken for a viral illness. Fever may be sustained, remitting, or intermittent and tends to parallel disease activity, serving as a useful clinical marker of systemic inflammation severity and treatment response.

Lymphadenopathy

Generalized or regional lymphadenopathy, involving at least two distinct node-bearing sites and with nodes typically exceeding 1 cm in diameter, occurs in the majority of DRESS patients. Lymph node enlargement may be painful and is sometimes prominent enough to suggest lymphoma as an alternative diagnosis, particularly when accompanied by significant lymphocytosis. Lymph node biopsy, when performed, may show reactive hyperplasia, pseudo-lymphoma patterns, or in severe cases hemophagocytic lymphohistiocytosis, which is a recognized life-threatening complication of DRESS.

Hematological Abnormalities

Eosinophilia is the hallmark hematological abnormality of DRESS and is present in the large majority of cases, though not universally so at any single time point. Peripheral blood eosinophil counts typically range from moderately elevated (700 to 1,499/μL) to markedly elevated (1,500/μL or above), with counts exceeding 3,000 to 5,000/μL in severe cases. The degree of eosinophilia correlates broadly with organ involvement severity and may fluctuate substantially during the clinical course, sometimes falling transiently with systemic corticosteroid therapy before rebounding during taper.

Atypical lymphocytosis, representing the peripheral blood appearance of activated, large, irregularly shaped lymphocytes (morphologically resembling Downey cells seen in infectious mononucleosis), is present in approximately 70% of DRESS cases. This atypical lymphocytosis reflects the clonal expansion of drug-specific T cells and is a highly discriminating feature relative to other drug hypersensitivity reactions.

Organ Involvement

Multi-organ involvement is a defining feature of DRESS and distinguishes it from uncomplicated drug exanthem. The liver is most commonly involved, with hepatocellular injury pattern (elevated alanine aminotransferase, ALT) present in 75 to 90% of cases. Hepatic involvement ranges from asymptomatic enzyme elevation to fulminant hepatic failure. The kidney (interstitial nephritis with elevated creatinine), lungs (pneumonitis, pleural effusion), heart (myocarditis, pericarditis, complete heart block), muscle (myositis with elevated creatine phosphokinase), and pancreas may all be involved. Less common but well-documented sites of involvement include the bone marrow (with cytopenias or hemophagocytosis), the gastrointestinal tract (colitis), the thyroid (early thyroiditis during the acute phase), and the central nervous system (encephalitis, meningitis).

The pattern of organ involvement varies among culprit drugs. Allopurinol-induced DRESS is associated with a particularly high rate of renal involvement. Carbamazepine-induced DRESS shows a predilection for liver involvement. Minocycline-induced DRESS characteristically produces pneumonitis. These drug-specific organ tropism patterns have important prognostic and management implications.

Development of the RegiSCAR Scoring System

The RegiSCAR (Registry of Severe Cutaneous Adverse Reactions) group was established in the early 2000s as a multinational European surveillance network for pharmacovigilance of severe cutaneous adverse drug reactions, including DRESS, SJS, TEN, and AGEP. The registry recruited cases from hospitals in France, Germany, Italy, the Netherlands, Israel, and Austria, providing a large, systematically collected dataset for epidemiological analysis.

Recognizing the critical need for a standardized DRESS case definition that could be applied uniformly across the participating centers and in the broader clinical and research community, the RegiSCAR group undertook a structured consensus and validation process to develop a scoring instrument. The resulting RegiSCAR DRESS score was formally published by Kardaun and colleagues in 2007 in the British Journal of Dermatology and has since become the internationally dominant standardized tool for DRESS case classification.

The score was constructed by operationalizing the key clinical criteria identified in prior DRESS case series and expert opinion into discrete, objectively assessable items with explicit scoring rules. The weighting of individual items reflects their discriminatory contribution to DRESS diagnosis relative to alternative diagnoses encountered in the differential diagnosis of febrile skin eruptions. Negative point values were assigned to criteria whose absence is more suggestive of DRESS than alternative diagnoses, introducing a bidirectional scoring framework that prevents high scores from being achieved by conditions sharing only partial features of DRESS.

Validation of the scoring system was performed against an expert-adjudicated reference standard using the RegiSCAR case database, with the four score tier cut-offs (less than 2, 2 to 3, 4 to 5, and 6 and above) determined to optimize diagnostic accuracy across the full spectrum of clinical presentations from definite DRESS to clear alternative diagnoses.

RegiSCAR Score Components and Scoring Rules

The RegiSCAR score has one mandatory criterion and eight scored domains. The mandatory criterion must be satisfied for the score to be applied; absence of hospitalization does not per se exclude DRESS but removes the score's validation basis. The scored domains yield a total ranging from a minimum of approximately -4 to a maximum of +9, with higher scores indicating greater probability of true DRESS.

Mandatory Criterion (Not Scored)

Hospitalization: The patient must be hospitalized for the condition being assessed. This criterion reflects the severity threshold required for DRESS classification and ensures that the score is not applied to mild or ambulatory drug reactions that lack the systemic severity characteristic of DRESS. Its role is as an eligibility criterion rather than a discriminating item within the score.

Scored Domain 1: Fever

Fever is defined as a temperature of 38.5°C (101.3°F) or above recorded at any point during the clinical course. The scoring for this item reflects the clinical observation that high fever is strongly associated with DRESS but not universally present, and its absence modestly reduces the probability of DRESS diagnosis.

Fever ≥38.5°C	Score
No	-1
Yes or Unknown	0

Scored Domain 2: Lymphadenopathy

Lymphadenopathy is defined as enlarged lymph nodes at two or more distinct anatomical sites, with each enlarged node measuring more than 1 cm in its greatest diameter. Assessment should include cervical, axillary, inguinal, and other accessible node-bearing regions. Tender and non-tender adenopathy are both counted. The presence of lymphadenopathy adds positive probability weight to the DRESS assessment.

Enlarged Lymph Nodes (≥2 sites, >1 cm)	Score
No or Unknown	0
Yes	+1

Scored Domain 3: Atypical Lymphocytes

Atypical lymphocytes are identified on peripheral blood smear review by a trained hematologist or pathologist. These cells are large, irregular, with abundant pale cytoplasm, eccentric nuclei, and prominent nucleoli, reflecting the activated T-cell phenotype of drug-specific effector cells. Their presence is a highly discriminating hematological feature of DRESS and is recorded as present or absent based on formal blood smear interpretation. A note of caution: morphological assessment of atypical lymphocytes requires expert smear review and should not be inferred from automated differential count data alone.

Atypical Lymphocytes on Smear	Score
No or Unknown	0
Yes	+1

Scored Domain 4: Eosinophilia

Eosinophilia is the most diagnostically important hematological finding in DRESS and is assigned the most granular scoring within this domain. The scoring accounts for two levels of eosinophilia severity, reflecting the dose-dependent relationship between eosinophil burden and organ involvement risk. When total white blood cell count is low (leukopenia), percentage eosinophilia thresholds (10% and 20%) may be substituted for the absolute count thresholds. The peak eosinophil count recorded at any time during the clinical course should be used for scoring rather than the count at a single time point.

Eosinophilia	Score
No (<700/μL or <10% if total WBC low)	0
700 to 1,499/μL (or 10 to 19.9% if total WBC low)	+1
≥1,500/μL (or ≥20% if total WBC low)	+2

Scored Domain 5: Skin Involvement

The skin domain encompasses three sub-items, each assessed independently and scored separately, with the total skin domain contribution being the sum of all three sub-item scores. Each sub-item captures a different dimension of the cutaneous presentation relevant to DRESS discrimination.

Sub-item 5a: Skin Rash Extent (≥50% BSA)

Extensive skin rash involvement covering at least 50% of the body surface area is characteristic of DRESS and distinguishes it from localized or limited drug exanthems. BSA estimation uses standard body surface mapping or the rule of nines. The rash must be the drug reaction rash itself rather than secondary dermatitis or pre-existing skin disease.

Skin Rash Extent ≥50% BSA	Score
No or Unknown	0
Yes	+1

Sub-item 5b: Skin Rash Morphology Suggesting DRESS

This sub-item assesses whether the morphological characteristics of the rash are suggestive of DRESS. At least two of the following four features must be present to score positively: (1) edema or facial puffiness superimposed on the rash, (2) skin infiltration giving the rash a palpable, raised quality, (3) purpuric components (particularly on the lower extremities), and (4) scaling of the rash surface. The negative score for absence of these features reflects that a rash lacking DRESS-typical morphology reduces the probability of the diagnosis.

Skin Rash Morphology Suggesting DRESS (≥2 of: edema, infiltration, purpura, scaling)	Score
No	-1
Yes or Unknown	0

Sub-item 5c: Skin Biopsy Suggesting DRESS

Histopathological evaluation of a skin punch biopsy from an affected area provides supportive evidence for DRESS diagnosis. Biopsy findings compatible with DRESS include interface dermatitis with vacuolar alteration of the dermo-epidermal junction, perivascular lymphocytic infiltrate with eosinophils, dermal edema, and absence of the full-thickness epidermal necrosis that characterizes SJS-TEN. The absence of biopsy evidence modestly reduces the DRESS score, reflecting the incremental diagnostic value of histopathological confirmation when performed.

Skin Biopsy Suggesting DRESS	Score
No	-1
Yes or Unknown	0

Scored Domain 6: Organ Involvement

Organ involvement beyond the skin is a critical discriminating feature of DRESS relative to other drug eruptions. The organs assessed include the liver, kidney, lung, muscle, heart, and pancreas, with specific threshold criteria for each:

• Liver: ALT ≥2× upper limit of normal (ULN), or elevated total bilirubin ≥2× ULN, or alkaline phosphatase ≥2× ULN, or LDH ≥2× ULN. Hepatocellular pattern (ALT elevation) is most common and most clinically significant.
• Kidney: Serum creatinine ≥1.5× ULN, reflecting tubulointerstitial nephritis as the predominant renal manifestation. Urinalysis may show eosinophiluria, hematuria, or proteinuria as additional supportive findings.
• Lung/Pneumonitis: Chest imaging (CT or radiograph) demonstrating bilateral infiltrates, ground-glass opacification, or consolidation attributable to pneumonitis; or oxygen saturation below 92% on room air; or need for supplemental oxygen or mechanical ventilatory support.
• Muscle/Myositis: Creatine phosphokinase (CPK) ≥2× ULN with or without myalgia or proximal muscle weakness.
• Heart: New electrocardiographic changes (ST-T wave abnormalities, heart block), echocardiographic evidence of myocardial dysfunction, or troponin elevation attributable to myocarditis.
• Pancreas: Serum lipase or amylase ≥2× ULN without alternative explanation.
• Other organs: Including thyroid, central nervous system, gastrointestinal tract, or other visceral involvement with objective evidence of end-organ dysfunction attributable to DRESS.

Number of Organs Involved (meeting threshold criteria)	Score
No organ involvement	0
1 organ involved	+1
≥2 organs involved	+2

Scored Domain 7: Time to Resolution ≥15 Days After Drug Discontinuation

The clinical course of DRESS is characteristically prolonged, with resolution of the skin rash and normalization of laboratory abnormalities typically requiring 4 to 6 weeks or more after the culprit drug is stopped. This prolonged resolution distinguishes DRESS from most other drug eruptions, which resolve within days to 2 weeks of drug discontinuation. The criterion is scored based on whether resolution of the acute reaction required more than 15 days from drug withdrawal. Cases where resolution timeline is unknown (e.g., due to death, transfer, or lost to follow-up) are scored as unknown (0) rather than negative.

Time to Resolution After Drug Discontinuation	Score
Less than 15 days (rapid resolution)	-1
15 days or more, or Unknown	0

Scored Domain 8: Exclusion of Alternative Diagnoses

This domain assesses the thoroughness of the alternative diagnosis workup and the negativity of key investigations that, if positive, would support an alternative non-drug-related etiology for the clinical syndrome. At least three of the following investigations must have been performed and returned negative results to score the positive point for this domain:

• Antinuclear antibody (ANA): negative (positive ANA suggests autoimmune connective tissue disease as alternative etiology)
• Blood cultures: negative (sepsis with drug reaction as alternative etiology)
• Serology for hepatitis A virus (HAV): IgM negative
• Serology for hepatitis B virus (HBV): surface antigen and IgM anti-core antibody negative
• Serology for hepatitis C virus (HCV): antibody negative
• Serology for Chlamydia species: negative
• Serology for Mycoplasma pneumoniae: negative

If fewer than three of these investigations were performed, or if any performed test returned a positive result, the domain scores zero. This domain design incentivizes comprehensive alternative diagnosis exclusion before assigning high-probability DRESS classification, reinforcing diagnostic rigor.

Alternative Diagnoses Excluded (≥3 investigations performed, all negative)	Score
No (fewer than 3 done, or any positive)	0
Yes (≥3 done and all negative)	+1

Total Score Calculation and Diagnostic Classification

The total RegiSCAR DRESS score is calculated by summing all domain scores. The minimum achievable score in a hospitalized patient with the worst-case negative items present and no positive items is approximately -4, while the maximum achievable score with all positive criteria at their highest levels is +9.

Domain	Minimum Points	Maximum Points
Fever ≥38.5°C	-1	0
Lymphadenopathy (≥2 sites, >1 cm)	0	+1
Atypical lymphocytes	0	+1
Eosinophilia	0	+2
Skin rash extent ≥50% BSA	0	+1
Skin rash morphology suggesting DRESS	-1	0
Skin biopsy suggesting DRESS	-1	0
Organ involvement	0	+2
Time to resolution ≥15 days	-1	0
Alternative diagnoses excluded	0	+1
Total	-4	+9

Diagnostic Classification by Score

Total RegiSCAR Score	Classification	Clinical Interpretation
Less than 2	No case	DRESS diagnosis excluded; alternative diagnoses should be pursued
2 to 3	Possible DRESS	Some features consistent with DRESS; insufficient criteria for probable or definite classification; continued monitoring, further workup, and specialist review recommended
4 to 5	Probable DRESS	Clinical presentation consistent with DRESS with significant probability; immediate management as DRESS appropriate while further diagnostic workup is completed
6 or above	Definite DRESS	Clinical and laboratory criteria fulfill DRESS diagnosis; full DRESS management protocol should be initiated without delay

Clinical Application and Scoring Workflow

Systematic application of the RegiSCAR score requires a structured approach to data collection that spans the clinical examination, laboratory evaluation, skin biopsy, and medical record review for temporal assessment.

Timing of Score Application

The RegiSCAR score may be applied at any point during the clinical course, but its discriminatory accuracy is maximized when applied after the full syndrome has declared itself, typically 5 to 10 days after presentation. Early application (within the first 48 to 72 hours of admission) may underestimate score totals, as eosinophilia may not yet be present, organ involvement may be developing, and the extent of skin involvement may be increasing. Serial scoring over the first 1 to 2 weeks of hospitalization is recommended to capture the peak disease expression and most accurate score.

For clinical management purposes, the RegiSCAR score should not delay empirical treatment decisions in patients with a high clinical index of suspicion for DRESS. When the clinical presentation is compelling, management should proceed while the diagnostic workup is completed and the formal score is calculated.

Data Collection Checklist

Accurate RegiSCAR scoring requires the following data elements to be systematically collected:

• Maximum recorded temperature since presentation (for fever criterion)
• Physical examination documentation of lymph node sites and sizes (for lymphadenopathy criterion)
• Peripheral blood smear report with specific comment on atypical lymphocytes (not automated differential)
• Complete blood count with differential, including absolute eosinophil count (peak value during clinical course)
• Body surface area estimation of rash extent, performed by experienced clinician or dermatologist
• Dermatology assessment of rash morphological features (edema, infiltration, purpura, scaling)
• Skin punch biopsy report (if performed), with specific comment on interface change, eosinophil infiltration, and absence of full-thickness epidermal necrosis
• Liver function tests (ALT, AST, total bilirubin, alkaline phosphatase, LDH) with comparison to ULN
• Renal function tests (serum creatinine) with comparison to ULN and baseline
• Chest imaging results (if pneumonitis suspected)
• CPK, troponin, amylase, and lipase (if myocarditis, myositis, or pancreatitis suspected)
• Documentation of date of drug discontinuation and clinical resolution date or status
• ANA result
• Blood culture results
• Hepatitis A, B, and C serologies
• Chlamydia and Mycoplasma serologies

Differential Diagnosis: DRESS versus Other Severe Drug Reactions and Mimics

The RegiSCAR scoring system was specifically designed to distinguish DRESS from other presentations that can mimic it clinically, and understanding the discriminating features is essential for accurate application of the score.

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS-TEN)

SJS and TEN are severe mucocutaneous drug reactions characterized by keratinocyte apoptosis leading to full-thickness epidermal detachment. Key distinguishing features from DRESS include: prominent and severe mucosal involvement (eyes, oral mucosa, genital mucosa) in SJS-TEN versus the mild or absent mucosal findings in DRESS; skin biopsy showing full-thickness epidermal necrosis in SJS-TEN versus interface dermatitis with eosinophils in DRESS; positive Nikolsky sign (lateral pressure causing epidermal separation) in SJS-TEN; and typically lesser degrees of eosinophilia and lymphadenopathy in SJS-TEN. Organ involvement can occur in both syndromes. A drug exposure causing DRESS in one patient can cause SJS-TEN in another, and very rarely an individual patient may transition between SJS-TEN and DRESS features (DRESS-SJS overlap), requiring careful clinical reassessment.

Acute Generalized Exanthematous Pustulosis (AGEP)

AGEP presents as an acute febrile eruption with hundreds of sterile, non-follicular superficial pustules on a background of erythema, predominantly affecting skin folds and the trunk. Key distinguishing features from DRESS include the pustular rather than morbilliform morphology, a shorter latency period (often 1 to 3 days from drug exposure rather than weeks), more rapid resolution (typically within 15 days), neutrophilia rather than eosinophilia as the predominant hematological finding, limited systemic involvement, and a skin biopsy showing subcorneal or intracorneal spongiform pustules with neutrophils rather than the interface dermatitis with eosinophils of DRESS. The EuroSCAR AGEP validation score (AGEP score) is the analogous instrument for AGEP, and the RegiSCAR group developed both instruments in parallel to enable confident differential classification between these syndromes.

Drug-Induced Hypersensitivity Syndrome (DiHS)

DiHS is the terminology used particularly in Japanese literature for what the Western literature more commonly calls DRESS. The two terms are largely synonymous clinically, though some authors reserve DiHS specifically for cases with documented herpesvirus reactivation. The Japanese DiHS diagnostic criteria developed by Shiohara and colleagues emphasize HHV-6 reactivation as a diagnostic criterion, whereas the RegiSCAR score does not formally incorporate herpesvirus serology (a practical recognition that herpesvirus testing is not universally available). Awareness of this terminological overlap is important when interpreting the international DRESS literature.

Viral Exanthem and Infectious Mononucleosis

Viral exanthems, particularly EBV-associated infectious mononucleosis, share multiple features with DRESS including morbilliform rash, lymphadenopathy, atypical lymphocytosis, fever, hepatitis, and elevated liver enzymes. The RegiSCAR score specifically mandates that EBV (assessed via heterophile antibody and/or EBV IgM serology), hepatitis viruses, and other infectious agents be excluded before a definite DRESS classification is assigned. Additionally, the history of a culprit drug exposure with an appropriate latency (2 to 8 weeks) provides critical context, and the subsequent course of viral exanthem (resolving within 2 to 3 weeks without treatment) contrasts with the prolonged DRESS course. Note that EBV reactivation can occur as part of DRESS itself, complicating this distinction; the pattern of reactivation (primary EBV infection in young patients presenting as classic mononucleosis versus reactivation of latent EBV in an older patient on a known DRESS-associated drug) helps guide interpretation.

Hemophagocytic Lymphohistiocytosis (HLH)

HLH is a life-threatening hyperinflammatory syndrome that may occur as a complication of DRESS or may mimic DRESS independently. When HLH complicates DRESS, features including high-grade fever, hepatosplenomegaly, pancytopenia, extremely elevated ferritin (often above 10,000 ng/mL), hypertriglyceridemia, and hemophagocytosis on bone marrow biopsy should be specifically sought, as HLH requires additional specific treatment (HLH-directed immunosuppression) beyond standard DRESS management. The HScore can be applied concurrently with the RegiSCAR score to assess HLH probability in DRESS patients with worsening systemic features.

Adult-Onset Still Disease (AOSD)

AOSD is a systemic autoinflammatory disorder that shares multiple features with DRESS including high-spiking fever, salmon-colored evanescent rash, lymphadenopathy, hepatitis, and leukocytosis with neutrophilia. Key distinguishing features include the typical salmon-pink evanescent rash of AOSD (appearing and disappearing with fever spikes) versus the persistent morbilliform rash of DRESS, neutrophilia rather than eosinophilia as the predominant hematological finding, markedly elevated ferritin (often above 3,000 ng/mL), absence of a culprit drug exposure with appropriate DRESS latency, and the absence of the full constellation of DRESS features. The RegiSCAR score's requirement for culprit drug identification and appropriate temporal relationship is critical in distinguishing AOSD from DRESS.

Management Implications of RegiSCAR Score Classification

The RegiSCAR classification tier directly informs management intensity and urgency, with higher scores warranting more aggressive and immediate therapeutic intervention.

Immediate Drug Discontinuation

For patients with possible, probable, or definite DRESS (RegiSCAR score 2 or above), all suspected culprit drugs should be identified and immediately discontinued. When multiple drugs have been started within 2 to 8 weeks of the reaction, all recently started medications should be stopped unless there is a compelling medical reason to continue a specific agent. The Naranjo algorithm and drug-specific temporal assessment tools can assist in ranking the probability that each co-administered drug is the culprit. Cross-reactivity within drug classes (particularly among aromatic anticonvulsants) must be carefully considered when selecting alternative medications for ongoing medical needs.

Systemic Corticosteroid Therapy

Systemic corticosteroids are the mainstay of immunosuppressive treatment for DRESS in patients with significant organ involvement, with prednisone or prednisolone typically initiated at doses of 0.5 to 2 mg/kg/day (or equivalent intravenous methylprednisolone in severe cases). The use of corticosteroids in DRESS is widely practiced but remains based on observational evidence rather than randomized controlled trials. The primary risk of corticosteroid therapy is reactivation of herpesvirus infections (particularly VZV and CMV) and immunosuppression-related secondary infections; concurrent antiviral prophylaxis and infectious disease consultation are recommended in severe cases. Corticosteroid tapering must be extremely slow (over 3 to 6 months or more) given the high risk of relapse with rapid taper. The RegiSCAR classification tier (probable or definite DRESS) provides a standardized threshold for corticosteroid initiation in institutional treatment protocols.

Organ-Specific Management

Management of organ involvement is guided by the specific organs affected and the severity of dysfunction. Hepatic involvement may range from conservative monitoring for mild enzyme elevation to emergency liver transplant evaluation for acute liver failure. Renal involvement requires nephrology consultation, fluid balance optimization, and avoidance of nephrotoxic agents. Cardiac myocarditis may necessitate continuous telemetry monitoring, echocardiography, and cardiology consultation. Pulmonary involvement may require supplemental oxygen, bronchodilators, and in severe cases mechanical ventilatory support. The RegiSCAR organ involvement domain score provides a structured framework for quantifying multi-organ involvement and tracking treatment response.

HHV-6 and Herpesvirus Management

Given the central role of herpesvirus reactivation in DRESS pathogenesis, HHV-6 DNA quantification in serum (by PCR) and testing for CMV, EBV, and VZV reactivation is recommended in all patients with probable or definite DRESS classification. Antiviral therapy with ganciclovir or valganciclovir may be considered for patients with documented HHV-6 or CMV reactivation with high viral loads and severe clinical course, though the evidence base for this intervention is limited to case series and expert opinion. Acyclovir or valacyclovir prophylaxis against VZV reactivation is generally recommended during corticosteroid therapy for DRESS.

Long-Term Follow-Up and Autoimmune Monitoring

Patients with confirmed DRESS (RegiSCAR score 4 or above) require structured long-term follow-up given the documented risk of autoimmune sequelae. Published cohort studies report development of thyroid autoimmunity (Hashimoto thyroiditis or Graves disease) in 17 to 25% of DRESS survivors, type 1 diabetes mellitus in approximately 7 to 10%, and various other autoimmune conditions including autoimmune hemolytic anemia, immune thrombocytopenia, and systemic lupus erythematosus in smaller proportions. A structured surveillance protocol including thyroid function tests (TSH, free T4) and thyroid antibodies, fasting glucose and HbA1c, and CBC with differential at 3, 6, and 12 months after discharge and annually thereafter is recommended.

RegiSCAR Score in Research and Pharmacovigilance

Beyond its clinical utility, the RegiSCAR score serves a critical function in standardizing DRESS case ascertainment in pharmacovigilance, post-marketing surveillance, and clinical research. Prior to the RegiSCAR score's widespread adoption, the heterogeneity in DRESS diagnostic criteria across published studies made between-study comparisons of incidence rates, drug causality attributions, and treatment outcomes essentially invalid. By providing a universally applicable, objective scoring framework, the RegiSCAR score enables the construction of DRESS case registries with consistent inclusion standards, supports regulatory submissions for drug safety signals, and facilitates meta-analytic synthesis of DRESS treatment and outcome data.

In pharmacovigilance databases such as VigiBase (WHO), EudraVigilance (EMA), and FAERS (FDA), the RegiSCAR score criteria are increasingly used as the basis for DRESS case definitions in signal detection algorithms, improving the specificity of DRESS case identification relative to non-standardized MedDRA-based queries. Pharmacogenomic research studies investigating HLA associations with DRESS, cytokine profiling studies, and T-cell immunology studies all use the RegiSCAR classification to ensure that enrolled cases represent genuine DRESS and not lower-probability DRESS mimics.

Limitations of the RegiSCAR Score

Despite its widespread adoption and validated performance, the RegiSCAR score has several important limitations that clinicians and researchers should recognize.

Dependence on Complete Data Availability

Accurate RegiSCAR scoring requires access to a comprehensive dataset including peripheral blood smear with atypical lymphocyte assessment, formal body surface area estimation of rash extent, dermatology evaluation of rash morphology, skin biopsy report, a panel of serological exclusion investigations, and serial laboratory monitoring. In resource-limited settings, outpatient or emergency settings, or cases where patients deteriorate rapidly before full workup is completed, some data elements may be unavailable, forcing clinicians to score items as "unknown" and potentially underestimating the score. The "unknown" scoring option (treated as 0 for most negative items) systematically biases toward lower scores when data are incomplete.

Temporal Application Challenges

The time-to-resolution criterion (Domain 7) cannot be fully assessed until the patient has either recovered or the 15-day threshold has been reached. This means that the definitive final score cannot be calculated in the early days of hospitalization, potentially delaying confident classification at the time when treatment decisions are most urgent. Clinicians should score the remaining seven domains during the acute phase and apply the resolution criterion retrospectively once the clinical course is known.

Absence of Herpesvirus Reactivation as a Formal Criterion

The RegiSCAR score does not incorporate herpesvirus reactivation (particularly HHV-6) as a scored criterion, despite substantial evidence for its pathogenic and diagnostic significance in DRESS. The Japanese DiHS criteria explicitly include HHV-6 reactivation as a core diagnostic element. This omission in the RegiSCAR score reflects the practical reality that herpesvirus PCR testing was not universally available at the time of the score's development, but it means that a distinctive and informative biological marker of DRESS is not captured within the formal scoring framework. Clinicians should consider herpesvirus serology and PCR as a supplementary assessment beyond the formal RegiSCAR score.

Scoring System Design for Case Classification Rather Than Severity Assessment

The RegiSCAR score is designed to classify the probability of DRESS diagnosis rather than to quantify DRESS severity or predict clinical outcomes. High RegiSCAR scores do not necessarily correlate with severe organ involvement or poor prognosis; a patient with definite DRESS (score 6 or above) may have mild hepatitis as the only organ involvement, while a patient with probable DRESS (score 4 to 5) may have severe multi-organ failure. Severity assessment requires additional tools beyond the RegiSCAR score, including evaluation of the number and type of organs involved, the degree of hepatic or renal dysfunction, and the presence of complications such as HLH.

Application in Pediatric Populations

The RegiSCAR score was developed and validated primarily in adult populations. While it has been applied in pediatric DRESS case reports and small case series, formal validation in pediatric cohorts is lacking. Age-appropriate reference ranges for laboratory values (particularly eosinophil counts and liver enzyme ULN values) differ between children and adults, potentially affecting scoring accuracy. Pediatric DRESS may also present with different organ involvement patterns and clinical course than adult DRESS, limiting the generalizability of the adult-derived score.

Key Clinical Takeaways

• The RegiSCAR Score classifies suspected DRESS as no case (score less than 2), possible (2 to 3), probable (4 to 5), or definite (6 or above) based on eight scored domains: fever, lymphadenopathy, atypical lymphocytes, eosinophilia, skin involvement (three sub-items), organ involvement, time to resolution, and exclusion of alternative diagnoses.
• Hospitalization is a mandatory prerequisite for score application and is not itself scored. The score's validation basis is in hospitalized patients with suspected severe drug reactions.
• Eosinophilia and organ involvement are the two highest-yield domains, each contributing up to 2 positive points, reflecting their central role in DRESS pathophysiology and diagnosis.
• Negative scoring items (absence of fever, absence of typical rash morphology, absence of compatible biopsy, and resolution within 15 days) actively reduce the score, appropriately distinguishing DRESS from partial mimics that share only some positive features.
• The score is maximally accurate when applied after peak disease expression (typically 5 to 10 days after admission) and when complete data from all domains are available; serial scoring during hospitalization captures disease evolution.
• Alternative diagnoses requiring systematic exclusion include infectious mononucleosis, viral hepatitis, Chlamydia, Mycoplasma, and systemic autoimmune disease; the alternative diagnosis exclusion domain incentivizes comprehensive workup.
• Management intensity scales with the RegiSCAR classification: immediate drug discontinuation for any score 2 or above; systemic corticosteroids for probable or definite DRESS with organ involvement; organ-specific management tailored to the pattern of involvement; and long-term autoimmune surveillance for all confirmed cases.
• The RegiSCAR score does not formally incorporate herpesvirus reactivation; HHV-6 PCR and herpesvirus serologies should be obtained as supplementary assessments in all probable and definite cases.
• Long-term follow-up for autoimmune sequelae (thyroid disease, type 1 diabetes mellitus, autoimmune cytopenias) is mandatory for patients with probable and definite DRESS classifications, with structured surveillance recommended for at least 12 months after discharge.